Floatz logo

Bacitracin

Primary Sclerosing Cholangitis (PSC)

Assistance Publique - Hôpitaux de ParismixturePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Primary Sclerosing Cholangitis (PSC) cohort.

Asset / SponsorPhaseRating
lum001
Mirum Pharmaceuticals, Inc.
Phase 2B
Obeticholic Acid
Intercept Pharmaceuticals
Phase 2CCC
NEOMYCIN
Assistance Publique - Hôpitaux de Paris
Phase 2CCC
ABBV-599 COMPONENT UPADACITINIB
RenJi Hospital
Phase 2CCC
Lb-P8
LISCure Biosciences
Phase 2CCC
IMMUNOGLOBULIN G4, ANTI-(HUMAN LYSYL OXIDASE HOMOLOG 2) (HUMAN-MUS MUSCULUS MONOCLONAL GS-6624 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL GS-6624 .KAPPA.-CHAIN, DIMER
Gilead Sciences
Phase 2CCC
Xifaxan
Mayo Clinic
Phase 1CC

Same molecule, other indications

Bacitracin is also rated in:

skin carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Inflammatory Bowel Disease (IBD)Dormant
CCC
Indicative ·
53 / 100
View asset →
Breast CancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →